

#### Stock Data

Share Price:	5.50p
Market Cap:	£4.07m*
Shares in issue:	74.06m*
52-week high/low:	12.30p/4.00p

\*Pre-Placing numbers

#### Company Profile

Sector:	Financial Services
Ticker:	IIG
Exchange:	AIM

#### Activities

Intuitive Investments Group plc ('Intuitive', 'IIG', 'the Company') is a closed-end investing company that seeks to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses that operate predominantly in the UK, continental Europe and the US, in order to generate capital growth over the long term for shareholders.

[www.iigplc.com](http://www.iigplc.com)

#### Share price performance since Admission\*



\*AIM Admission took place on 14 December 2020. Source: [LSE](https://www.lse.com)

Past performance is not an indication of future performance.

#### Turner Pope contact details

Tel: 0203 657 0050  
Email: [info@turnerpope.com](mailto:info@turnerpope.com)  
Web: [www.turnerpope.com](http://www.turnerpope.com)

Andrew Thacker  
Corporate Broking & Sales

Barry Gibb  
Research Analyst

TPI acts as sole broker to Intuitive Investments Group plc

Attention is drawn to the disclaimers and risk warnings at the end of this document.

Retail clients (as defined by the rules of the FCA) must not rely on this document.

## Intuitive Investments Group

Subject to shareholder approval, IIG has yesterday proposed cancellation of trading on AIM and admission to trading on the London Stock Exchange's ('LSE') Specialist Fund Segment ('SFS'). Taking place in conjunction with the conditional appointment of a new keynote Non-Executive Chairman, namely Sir Nigel Rudd, the Board is also proposing a series of transformative measures ('the Proposals') including the adoption of a new investment policy, the granting of general authority to allot Ordinary Shares and disapplication of statutory pre-emption rights. As part of this corporate action, IIG intends to provide Qualifying Shareholders with the ability to realise some or all of their shareholding in the Company through a proposed Tender Offer under which up to c.12.9 million would be purchased by Places procured by Turner Pope at a price of 5.25 pence per Ordinary Share. If the maximum number of Ordinary Shares under the Tender Offer is acquired, this will result in an amount of £675,000 being returned to Qualifying Shareholders.

### Reason for Admission onto the Specialist Fund Segment

A letter published today ('the Chairman's Letter') by IIG's present Chairman, Julian Baines, sets out the background to and reasons for the Proposals and why the Directors believe the Proposals, including the cancellation of trading on AIM and admission to trading on the SFS and the Tender Offer, to be in the best interests of the Company and its Shareholders as a whole. More specifically, the Directors believe that IIG's migration from AIM to the SFS will:

- Further enhance the Company's profile and brand recognition with investee companies;
- Extend the Company's shareholder base to a wider group of institutional shareholders;
- Assist in the recruitment, retention and incentivisation of employees;
- Support IIG's growth strategy.

Therefore, conditional, amongst other things, on the passing of resolutions at the Company's General Meeting, the Company will:

- Adopt the new investment policy
- In accordance with AIM Rule 41, cancel the Company's admission to trading on AIM at 0:7:00hrs on 8 August 2023, followed by admission to the SFS one hour later;
- Have general authority to issue and allot 1.25 billion new Ordinary Shares and;
- Have authority to issue and allot 3.7 billion Ordinary Shares for cash.

### Participation in the Tender Offer

The [Chairman's Letter](#) contains details on the procedure that should be followed by those Qualifying Shareholders who wish to participate in the Tender Offer. Shareholders are referred to Part 3 of the Chairman's letter for further information on the Tender Offer. For the avoidance of doubt, Shareholders are not obliged to tender their Ordinary Shares in the Tender Offer. Accompanying the Chairman's letter, a [Prospectus](#) has also been published, which is now available on the [Company's website](#).

### Notice of General Meeting

The Company is seeking Shareholders' approval of the Proposals at a General Meeting to be held on 28 July 2023 at midday.

**EXPECTED TIMETABLE OF PRINCIPAL EVENTS<sup>1</sup>**

Tender Offer Record Date	10 July 2023
Announcement of the proposed AIM Cancellation and Tender Offer and posting of this Document and Form of Proxy to Shareholders	11 July 2023
Tender Offer opens	11 July 2023
Latest time and date for receipt of Forms of Proxy	Midday on 26 July 2023
Latest time and date for receipt of TTE Instructions from CREST Shareholders in relation to the Tender Offer (i.e., close of Tender Offer)	1.00 p.m. on 26 July 2023
General Meeting	Midday on 28 July 2023
Announcement of results of the Tender Offer (Effective Date)	28 July 2023
Tendered Ordinary Shares placed with Placees	1 August 2023
CREST accounts credited for revised holdings of, and Tender Offer proceeds for, Ordinary Shares	By 1 August 2023
Last day of dealings in the Ordinary Shares on AIM	7 August 2023
Cancellation of admission of the Ordinary Shares to trading on AIM	7.00 a.m. on 8 August 2023
Admission and commencement of dealings in Ordinary Shares on the Specialist Fund Segment	8.00 a.m. on 8 August 2023

<sup>1</sup>All times are references to London times. Each of the above times and dates is based on the Company's expectations as at the date of this Document. If any of the above times and/or dates change, the revised times and/or dates will be notified to Shareholders by an announcement through a Regulatory Information Service ('RIS')

**LIST OF RESOLUTIONS<sup>1</sup>**

Resolution 1	Proposed change to the investment policy
Resolution 2	Migration to the Specialist Fund Segment
Resolution 3	General authority to allot Ordinary Shares
Resolution 4	Disapplication of pre-emption rights

<sup>1</sup>Refer to Part 2 of the Chairman's Letter for further details on the Proposals

**ADMISSION STATISTICS**

No. of Ordinary Shares <sup>(1)</sup>	74,064,551
No. of warrants to subscribe for Ordinary Shares in issue <sup>(1)</sup>	2,212,500
Market price per Ordinary Shares <sup>(2)</sup>	5.0 pence
Market capitalisation at Admission <sup>(2)</sup>	£3,703,228

(1) As at 7 July 2023, the latest practicable date prior to the publication of this document. (2) Based on the mid-market closing price of the Ordinary Shares as traded on the LSE on 7 July 2023, being the latest practicable date prior to the publication of this document. There can be no assurance that the market price of an Ordinary Share will trade at the same price as they previously traded on AIM.

**PLACING PROGRAMME STATISTICS**

Maximum size of the Placing Programme	1.25 billion Ordinary Shares
Minimum Placing Programme Price	In respect of the Ordinary Shares, at least Net Asset Value ('NAV') per Share plus a premium intended to at least cover the costs and expenses of the relevant Placing (including, without limitation, any placing commissions)

**THE DEALING CODES FOR THE ORDINARY SHARES WILL BE AS FOLLOWS:**

ISIN	GB00BNGFMW59
SEDOL	BNGFMW5
Ticker	IIG

Source: [IIG Chairman's Letter](#), [Prospectus](#)

## Conditional appointment of Sir Nigel Rudd as Non-Executive Chairman

Sir Nigel Rudd, a very high reputation, keynote executive and non-executive, is proposed to become IIG's Independent Non-Executive Chairman. Over the past 25 years, Sir Nigel has very successfully undertaken the role of Chairman at a number of the UK's largest companies, including Pendragon plc, the automotive retailer; Pilkington, a manufacturer of glass and glazing systems; Alliance Boots, a global retail pharmacy; Heathrow, the UK airport; Invensys plc, an engineering firm; Business Growth Fund Limited, an investor in growth companies; Signature Aviation plc, the aviation firm; and Meggitt plc, the aerospace and defence firm. He also occupied a seat on the Barclays Bank Board for more than 12 years, latterly as Deputy Chairman, retiring in 2008. Sir Nigel's appointment remains conditional on all of the Resolutions being passed at the General Meeting and admission to trading on the SFS. Julian Baines, MBE, the current Independent Non-Executive Chairman of the Company, will step down as Chairman and become an Independent Non-Executive Director of the Company. Other Directors of the Company will continue to comprise Malcolm John Gillies, Colin Willis, both all of which are Non-executive Directors ('NED') and are independent of the Investment Team, along with Robert Naylor, who retains the role of Chief Executive Officer.

Following today's proposed corporate action, IIG's Investment Team will remain David Evans, Robert Naylor and Dr Stewart White and its Advisory Panel will continue to comprise Ron Long, Per Matsson and Alastair Smith. These individuals introduce particular expertise in the Life Sciences, Healthcare and Technology industries to support the Board's identification, assessment and appraisal of potential investment opportunities and to provide general guidance to the Board where required.

## Proposed change in IIG's investment policy

The revised investment policy broadens the Company's remit to technology, as well as healthcare and life sciences companies and the geography where the Company may invest to include APAC. The Company is targeting an average return to shareholders of 20% capital growth per annum. The Board will seek to exploit the differential in valuations of life sciences and technology companies in different territories. There are many examples in which the team have been involved, for example Sir Nigel Rudd setting up and Chairing the Business Growth Fund; David Evans and Julian Baines, working with companies and partnering with institutions in other jurisdictions, such as taking UK life sciences intellectual property and partnering with US healthcare providers leading to the commercialisation of products. Malcolm Gillies has wide international experience of working with technology and other businesses. Overall, the Directors believe this change will allow the Board more flexibility in generating Shareholder returns. The complete, revised investing policy, which includes certain defined restrictions, summarised below is set out in full in Part 2 of the Chairman's Letter.

To achieve its investment objective, the Company will invest in early and later-stage life sciences, healthcare and technology businesses. It will follow a high conviction investment strategy and expects to hold a concentrated portfolio of investments while seeking to reduce concentration risk through diversification. The opportunity available will dictate the number of holdings and the weighting of investments in the portfolio. Investments are expected to be mainly in the form of equity and equity-related instruments, including convertible debt instruments. The equity interest in any investment may range from a minority position to 100% ownership. The Company's strategy will be to invest both in unquoted companies and those whose ordinary shares are publicly traded. It may acquire investments directly or by way of holdings in special purpose vehicles, intermediate holding companies or subsidiary entities, while possibly also investing in limited liability partnerships and other forms of legal entity.

The Company may, in the future, raise debt finance if it believes it will enhance Shareholder returns over the longer term. If, in the future, the Board does decide to introduce gearing, it would seek to maintain this at a conservative level, intending to limit the Company's borrowings to a maximum of 25 % of NAV at the time any loan is secured.

## Proposed migration to the Specialist Fund Segment

The Directors believe Resolution 2, proposing the Company from AIM to the SFS to be in the best interests of the

Company and its Shareholders as a whole. A comparison of LSE's AIM, Premium Main Market and SFS as a fund's route for trading is provided in the Appendix 2.0 of this Research Update.

The SFS is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the SFS. The SFS is only suitable for investors: (i) who understand the potential risk of capital loss and that there may be limited liquidity in the underlying investments of the Company; (ii) for whom an investment in securities admitted to trading on the SFS is part of a diversified investment programme; and (iii) who fully understand and are willing to assume the risks involved in such an investment portfolio. It should be remembered that the price of the Ordinary Shares can go down as well as up.

### **Proposed authority to allot Ordinary Shares and disapplication of statutory pre-emption rights**

The Directors consider that further share issuance will have the following benefits:

- Enhance the NAV per Ordinary Shares through the issuance of Ordinary Shares at a premium to the prevailing published NAV per Ordinary Share;
- Grow the Company, thereby spreading operating costs over a larger capital base which should reduce the ongoing charges ratio;
- The Company will be able to raise additional capital promptly, allowing it to take advantage of future investment opportunities as and when they arise;
- Further diversifying the Company's portfolio of investments; and
- Improve liquidity in the market for Ordinary Shares.

The minimum price at which Ordinary Shares will be issued pursuant to the Placing Programme or in consideration for investments, will be equal to the prevailing published NAV per Share at the time of issue together with a premium to at least cover the costs and expenses of the relevant Placing of Ordinary Shares (including, without limitation, any placing commissions). Any Ordinary Shares issued for non-cash consideration may be subject to a third-party valuation from an appropriate qualified independent adviser.

The Directors intend to continue to issue Ordinary Shares when they consider it to be in the best interests of Shareholders and the Company as a whole to do so and, with respect to such issuances, the Directors consider it to be advantageous to have the flexibility conferred by Resolution 4 within the Chairman's Letter to conduct an offering without complying with the strict requirements of the statutory pre-emption provisions. Resolution 4 will permit the Directors to allot equity securities for cash up to a maximum number of 1.25 billion Ordinary Shares (representing approximately 16.8 times the Company's estimated issued Ordinary Share capital) pursuant to the authority granted under Resolution 3 above, without complying with the pre-emption rights in the Companies Act. This power will be in substitution for the corresponding power granted by Shareholders on 17 January 2023.

### **Placing Programme and Consideration Shares**

Subject to the passing of certain resolutions at the Company's General Meeting, the Company may issue up to 1.25 billion Ordinary Shares in aggregate pursuant to the Placing Programme. Any Ordinary Shares issued pursuant to the Placing Programme will be issued at a price calculated by reference to the prevailing published NAV per Share at the time of issue together with a premium intended to at least cover the costs and expenses of the relevant Placing (including, without limitation, any placing commissions) which are not expected to exceed 2% of any such Placing. Ordinary Shares issued under the Placing Programme may be issued under this document provided that it is updated by a supplementary prospectus (if required). Further details about the Placing Programme are set out in Part 4 of the Prospectus. Shareholders' pre-emption rights over this unissued share capital have been disapplied.

Subject to the passing of the resolutions at the Company's General Meeting, the Company may issue up to 3.7 billion Ordinary Shares in aggregate as vendor consideration on the acquisition of assets. Any Ordinary Shares will be issued

at a price calculated by reference to the prevailing published NAV per Share at the time of issue together with a premium intended to at least cover the costs and expenses of the relevant acquisition. Any Ordinary Shares issued for non-cash consideration may be subject to a third-party valuation from an appropriate qualified independent adviser.

### **Proposed Tender Offer, its financing, irrevocable undertakings, tendering process and Placing**

The Board recognises that, following the Company's AIM Cancellation, the Company will no longer be subject to the AIM Rules for Companies or be required to retain the services of an independent nominated adviser. The Specialist Fund Segment will provide a more flexible regulatory regime than AIM. The Board therefore intends to provide Qualifying Shareholders with the ability to realise some or all of their shareholding in the Company through a Tender Offer under which up to 12,857,142 Ordinary Shares (representing approximately 17.4 per cent. of the existing issued ordinary share capital of the Company) held by Qualifying Shareholders would be purchased by Placees procured by Turner Pope at a price of 5.25 pence per Ordinary Share. This compares with the Director's estimate of the Company's net assets as at 7 July 2023 of £9.26 million, equivalent to c. 12.5 pence per share. If the maximum number of Ordinary Shares under the Tender Offer is acquired, this will result in an amount of approximately £675,000 being returned to Qualifying Shareholders.

The Company has received irrevocable undertakings from Shareholders, including Directors, holding in aggregate 46,194,279 Ordinary Shares (representing approximately 62.4 per cent. of the existing issued ordinary share capital of the Company) not to tender their Ordinary Shares under the Tender Offer. Therefore, each Qualifying Shareholder is entitled to tender 46.1 per cent. of the Ordinary Shares held by them at the Record Date, rounded down to the nearest whole number of Ordinary Shares at a price of 5.25 pence per Ordinary Share ('Basic Entitlement').

The Company has sufficient cash resources to undertake the Tender Offer, however, as a relatively new company investing in early-stage healthcare companies, the Company has no distributable reserves from which to repurchase its own Ordinary Shares. Therefore, Turner Pope has conditionally placed £675,000 Ordinary Shares with Placees. The demand generated by Turner Pope, under the Placing, will firstly be used to purchase existing Ordinary Shares validly tendered under the Tender Offer, and secondly, the Company will issue new Ordinary Shares to satisfy any remaining demand not able to be met by existing Ordinary Shares tendered under the Tender Offer.

**Note: The Tender Offer is not open to Shareholders who hold their Ordinary Shares in certificated form. The Tender Offer will close at 1.00 p.m. on 26 July 2023 and tenders received after that time will not be accepted (unless the Tender Offer is extended).**

### **Minimum market capitalisation and removal of the Performance Fee**

Although there is no specific rule in respect of minimum market capitalisation in the LSE's Admission and Disclosure Standards, to give added investor protection and to ensure that the Company is not subscale, the Board will undertake to propose to continue as an investment company, by ordinary resolution, at each Annual General Meeting, if the Company's market capitalisation is less than £100 million. The market capitalisation is to be calculated on the Company's average closing share price in the 30 trading days prior to the Company's year-end.

As set out in the Company's AIM admission document dated 8 December 2020, the Company had a performance fee, payable to the Investment Team, based on 20 per cent. of realised profits calculated on an annual basis once the initial IPO proceeds of £7.85 million have been doubled by way of cash realisations. In agreement with members of the Investment Team, the Remuneration Committee has cancelled the Performance Fee and will look to establish new incentivisation for key members on the Investment Team once the Company has migrated to the Specialist Funds Segment. These arrangements may include share options, warrants and cash payments.

### **Effect of the AIM Cancellation**

Shareholders attention is drawn to the Risk Factors and Voluntary Compliance with the Listing Rules sections of the

Prospectus. Following the Company's AIM Cancellation, the Company will no longer be subject to the AIM Rules for Companies or be required to retain the services of an independent nominated adviser (NOMAD). The Specialist Fund Segment will provide a more flexible regulatory regime. For example, when making an investment, the Company must comply with certain Class Tests as set out in the AIM Rules. However, as a closed-end Investment Company admitted to trading on the SFS, if an investment is in line with the Company's investment policy and deemed by the Directors to be in the ordinary course of business, there would be no class tests. In such an instance, an investment of a certain size would result in a reverse takeover on AIM and for the Company to, amongst other things, prepare an admission document and seek re-admission to AIM, which would not be the case on the Specialist Fund Segment.

## General Meeting, irrevocable undertakings and intentions of the Directors

Notice convening the General Meeting to be held at Parklands Hotel & Country Club Crookfur Park, Ayr Road, Newton Mearns Glasgow G77 6DT at midday on 28 July 2023, at which the Resolutions will be proposed as set out in Part 5 of the Chairman's Letter. The Proposals are conditional, amongst other things, upon the Resolutions being duly passed.

The Company has received an irrevocable undertaking from Shareholders and Directors holding to vote in favour of the Resolutions. These Shareholders also wish to continue to support the Company's growth strategy on the Specialist Fund Segment as ongoing Shareholders and therefore do not wish to sell their current shareholdings. They have therefore irrevocably undertaken not to tender their Ordinary Shares under the Tender Offer.

## Should you wish to participate in the Tender Offer

The Directors consider the Resolutions to be proposed at the General Meeting to be in the best interests of the Company and its Shareholders as a whole and accordingly recommend that Shareholders vote in favour of the Resolutions. If you are a Qualifying Shareholder, however, and wish to tender some or all of your Ordinary Shares, you should send a TTE Instruction and follow the procedures set out in Part 3 of the Chairman's Letter in respect of tendering uncertificated Ordinary Shares.

If you have any questions about the procedure for tendering Ordinary Shares or making a Transfer-To-Escrow ('TTE') Instruction, you require extra copies of this Document, please telephone the Shareholder Helpline on +44 (0) 121 585 1131. Lines are open from 9.00 a.m. to 5.00 p.m. (London time) Monday to Friday (except public holidays in England and Wales). Please note that calls to these numbers may be monitored or recorded for security and training purposes. Please note that for legal reasons the Shareholder Helpline will only be able to provide information contained in this Document and will be unable to give advice on the merits of the Tender Offer or to provide financial, investment or taxation advice. You are advised to read all of the information contained in this Document before deciding on the course of action you will take in respect of the General Meeting and the Tender Offer.

## IIG's interim report for the six months to 31 March 2023

The Company released its interim results for the six months to 31 March 2023 on 29 June 2023. Further updated financial highlights were then detailed in the Prospectus, as follows:

	31 March 2023	30 September 2022	31 March 2022	30 September 2021
<b>Net Assets</b>	£9.42 million	£12.93 million	£12.33 million	£8.14 million
<b>Investments</b>	£7.86 million	£11.16 million	£10.40 million	£5.74 million
<b>Cash</b>	£1.23 million	£1.55 million	£1.91 million	£2.57 million
<b>NAV per share*</b>	13.07p	18.00p	18.73p	20.14p
<b>% Increase/(decrease) in NAV from previous period end</b>	(27.38)%	(3.90)%	(6.96)%	2.99%

\*Note: The Directors estimate IIG's net assets as at 7 July 2023 to be £9.26 million, equivalent to c.12.50p/share as of that date

Source: IIG, [Prospectus](#)

Operations highlights for the six months to 31 March 2023 and post period were as follows:

- Follow-on investment in Yourgene Health plc\* of £150,407 to acquire 50 million shares at a price of 0.3 pence per share. IIG holds 51,584,920 ordinary shares, or 1.62%, of the issued share capital of Yourgene.
- Reorganisation of investment in Sanondaf, including reduction in deferred consideration.
- Post period end follow-on investment in Light Science Technologies Holdings plc of £150,000 to acquire 15 million shares at a price of 1 penny per share. IIG holds 28,280,000 ordinary shares, or 8.49%, of the issued share capital of Light Science Technologies in total.
- As announced on 24 May 2023 Touchless Innovations spun-out its UK subsidiary, Touch-Less Hygiene, to be held directly by the Company along with a reduction in the deferred consideration payable to the vendors of business and assets of Sanoserv International Franchising Limited.

### **Sanondaf - Reduction in deferred consideration included with Interim results**

The consideration payable by Touchless Innovation to the vendors included £900,000 of deferred consideration payable six months from completion, due on 25 August 2022. In substitution for this amount, the Boards of IIG and Touchless Innovation agreed to issue the vendors 2,000,000 new ordinary shares of 1 penny each in IIG, as well as allowing the vendors the master franchise for Malta for nine years. The minimum royalty amount under the master franchise agreement is US\$5,400 per annum. In addition, the vendors no longer have the right to appoint a director to the Board of Touchless Innovation.

The Touchless Group continues to trade profitably and make significant progress:

- Touch-Less Hygiene, in selling machines and consumable product alongside the existing extensive franchise network; and
- Touchless Innovation has an extensive sales pipeline in the US which the Board believe will convert to sales imminently.

For the year ended 30 September 2022 the Touchless Group reported unaudited turnover of £1.94 million, profit after tax of £142,000, has net assets of £2.24m including cash of £423,000.

### **Net Asset Value ('NAV')**

Taking into account investment losses incurred by the Company of £3.44 million (comprising unrealised losses of £3.49 million, interest income from the convertible loan notes of £44,000, and management fee income of £12,000), along with administrative costs of the business for the period of £193,000, the overall loss amounted to £3.51 million. This reduced IIG's NAV of £12.93 million (or 18.00p/share) on 30 September 2022 to £9.42 million\* (or 13.07p/share) on 31 March 2023.

### **IIG's portfolio – Publicly traded and unquoted company investments as of 31 March 2023**

Extracted directly from IIG Interim report to 31 March 2023 that was released on 29 June 2023, Appendix 3 lists the valuation of the Company's quoted holdings at period end, while Appendix 4 summarises progress of each of its later stage investments.

*\*The Prospectus notes the Directors estimated IIG's NAV as at 7 July 2023 to be £9.26 million, equivalent to c.12.50p/share as of that date.*

## Appendix

### 1.0 Specialist Fund Segment

The LSE's SFS currently lists in excess of 40 funds with a total market value of over US\$14 billion:

- The SFS is the LSE's dedicated segment for specialist, closed-end investment funds targeting institutional, professional, professionally advised and knowledgeable investors.
- SFS can accept a variety of sophisticated legal structures, providing the flexibility for structures that can comply with home-country tax or securities laws while also allowing access to permanent capital via admission to an international market.
- As a regulated market, securities listed on SFS will normally be acceptable to institutional mandates.
- Securities will be traded on either the Stock Exchange Electronic Trading Service ('SETS') or the LSE Electronic Trading Service: Quotes and Crosses ('SETSqx') trading service, depending on the profile of the security and the relevant settlement-clearing arrangements. SETS is an electronic order book with integrated market-maker liquidity. SETSqx is a trading service for securities that are less liquid than those traded on SETS.

### 2.0 Comparison of funds routes to LSE markets

	Premium Main Market	SFS	AIM
<b>Transferable securities to be freely negotiable</b>	✓	✓	✓
<b>Type of funds</b>	Closed ended	Closed ended	Closed ended
<b>Offering document</b>	UKLA approved prospectus	UKLA approved prospectus	AIM admission document
<b>Audited historical financial information</b>	3 years*	3 years*	3 years*
<b>UK Corporate Governance Code</b>	Applies	X	Code of choosing
<b>Sponsor/NOMAD</b>	Sponsor	X	NOMAD
<b>Free float</b>	10%	No prescriptive free float	No prescriptive free float
<b>Working Capital Statement</b>	Unqualified for 12 months	PD disclosure - can be qualified	Unqualified for 12 months
<b>Investment diversification</b>	✓	X	X
<b>No more than 10% invested in other closed ended funds</b>	✓	X	X
<b>Feeder funds</b>	✓ (The feeder has to control the master)	✓	✓

\*or such shorter period that the entity has been in operation

Source: [London Stock Exchange](#)



### 3.0 Valuation of IIG's quoted investment portfolio

The following valuation tabulation was extracted from IIG's Prospectus that was released on 11 July 2023:

<b>IIG Quoted Investment Portfolio</b>	<b>Unaudited valuation as at</b>	<b>Unaudited valuation as at</b>	<b>Audited valuation as at</b>
	<b>7 July 2023</b>	<b>31 March 2023</b>	<b>30 Sept. 2022</b>
	£	£	£
Evgen Pharma plc	66,719	80,937	65,625
Light Science Technologies Holdings plc	282,800	531,200	863,200
Microsaic Systems plc	19,200	92,160	88,400
Biodexa Pharmaceuticals plc (previously Midatech Pharma plc)	12,688	1,365	26,250
Polarean Imaging plc	95,833	89,583	175,000
Shield Therapeutics plc	58,705	50,000	75,000
Trellus Health plc	25,500	27,625	29,750
Yourgene Health plc <sup>1</sup>	247,608	141,859	71,321
<b>Closing fair value</b>	<b>809,053</b>	<b>1,014,729</b>	<b>1,394,546</b>

<sup>1</sup> Note that on 3 July 2023 Yourgene received a Recommended Cash Offer from Novacyt UK Holdings Limited (a wholly-owned subsidiary of Novacyt S.A.), under the terms of which shareholders will be entitled to 0.522 pence per share.  
Source: IIG, [Prospectus](#)

#### 4.0 Valuation of IIG's quoted investment portfolio

The following valuation tabulation was extracted from IIG's Prospectus that was released on 11 July 2023:

<b>IIG's Unquoted Investment Portfolio</b>	<b>Method of fair value valuation</b>	<b>Unaudited valuation as at</b>	<b>Unaudited valuation as at</b>	<b>Audited valuation as at</b>
		<b>7 July 2023</b>	<b>31 March 2023</b>	<b>30 Sept. 2022</b>
		<b>£</b>	<b>£</b>	<b>£</b>
<b><u>Later stage investments</u></b>				
BioQ Pharma Inc	Cost, interest and FX move	996,620	977,344	1,027,438
Touchless Innovations Limited	Investment Team valuation	1,807,500	1,750,000	6,364,664
Touchless Hygiene Limited	Investment Team valuation	1,807,500	1,750,000	-
<b><u>Series A and B investments</u></b>				
Axol Bioscience Limited	Cost	249,092	249,092	249,092
CardiNor AS	Cost plus FX movement	112,891	112,891	122,260
The Electro Spinning Company Limited	Cost	500,000	500,000	500,000
Micrima Limited	Cost plus accrued interest	233,449	229,636	222,406
Momentum Bioscience Limited	Last investment round	125,000	125,000	125,000
Ocutec Limited	Last investment round	312,500	250,000	250,000
PneumoWave Limited	Last investment round	904,124	904,124	904,124
<b><u>Closing fair value</u></b>		<b><u>7,048,676</u></b>	<b><u>6,848,087</u></b>	<b><u>9,764,984</u></b>

Source: IIG, [Prospectus](#)

## 5.0 Review of IIG's unquoted investment portfolio

The following summary details regarding IIG's unquoted investment portfolio was extracted from IIG's Prospectus that was released on 11 July 2023:

### Later stage investments

**BioQ Pharma Incorporated ('BioQ')** - Investment of US\$1 million by way of unsecured convertible loan notes and warrants, valued at cost plus accrued interest. BioQ has raised more than US\$30 million in subscription for the CLN and is looking to prepare for a fundraising in the Series E ordinary shares. A further update is expected by the company before the calendar year end.

BioQ is a commercial-stage, medical device and pharmaceutical company, addressing the infusible drugs market. BioQ's proprietary Invenious™ platform comprises a "connect-and-go" drug-device system combination, which can be utilised to improve the delivery of infusible medicines. BioQ's platform includes a bespoke unit-dose delivery solution for infusible drugs, whereby a diluent delivery system and administration line are combined in one self-contained, ready-to-use presentation. The key benefits of the platform include reduced cost and complexity compared to current infusion techniques.

**Touchless Innovation Ltd ('Sanondaf')** - Investment of £1.81 million to acquire the entire issued share capital, held at fair value, for which cost is deemed the most appropriate basis of measurement.

Touchless Innovation is an international licensing and franchising business, with master franchise agreements in ten countries. Sanondaf licenses the brands, know-how and intellectual property of specialist disinfection and decontamination technology.

**Touch-Less Hygiene Ltd ('Touch-Less Hygiene')** - Investment of £1.81 million to acquire the entire issued share capital, held at fair value, for which cost is deemed the most appropriate basis of measurement.

Touch-Less Hygiene is a market-leading provider of specialist disinfection and decontamination services and has 25 regional sites in the UK. Treatments are non-corrosive, contain no toxic ingredients and Sanondaf's application methods ensure they are not harmful to people, animals or the environment. It is safe for use in all settings, including operating theatres, critical care units, and is CASA (Civil Aviation Safety Authority) approved. Sanondaf's disinfection formula has proven efficacy against pathogens, included, viruses, mould, bacteria and fungi. Customers include the blue-chip life sciences companies, essential infrastructure firms and the NHS. Touchless Hygiene holds a master franchise agreement from Touchless Innovation Ltd to operate in the UK.

### Series A and B investments

**Axol Bioscience Ltd ('Axol')** - Investment of £249,092 in A ordinary shares, held at fair value, for which cost is deemed the most appropriate basis of measurement. The company undertook a fundraising in April 2022 at the same valuation as IIG's investment.

Axol produces high quality human cell products, particularly in relation to pluripotent stem cell and critical reagents such as media and growth supplements, which are sold to medical research and drug discovery organisations. Axol also provides contract research for example customising cell lines for customers, such as reprogramming and differentiation. The Chairman of Axol is Jonathan Milner, who was previously deputy chairman of Abcam plc.

**CardiNor AS (CardiNor')** - Investment of £112,891 in ordinary shares, held at fair value, for which cost is deemed the most appropriate basis of measurement. CardiNor has made excellent progress particularly with the amount of money raised, which includes:

- Elisa test CE marked with clear route to market in the Europe and next generation magnetic test being developed.
- RuO in the US, but distribution deal done with IBL and talking to Labcorp. Going for full FDA approval.

Valuation is 80 million NOK (c.£7.0 million). CardiNor is a Norwegian biotech company established in June 2015 to commercialise the development of secretoneurin ("SN"), an important new biomarker for cardiovascular disease ("CVD"). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. CardiNor has completed development of a research assay based on immunoassay technology to measure SN in blood and the assay is under further clinical development, allowing it to obtain a CE mark.

**The Electrospinning Company Ltd ('TECL')** - Investment of £500,000 in ordinary shares, held at fair value, for which cost is deemed the most appropriate basis of measurement.

Held at cost, TECL is trading in line with management expectations. TECL has a technology platform built around the process of electrospinning, a technique for production of micro and nano-fibre biomaterials from a variety of natural and synthetic polymers, and a suite of post-processing technologies to convert the biomaterials into medical device components. The core business is the sale of product development and manufacturing services to medical device companies. TECL is also using its know-how to develop proprietary materials for targeted out-licensing opportunities, aiming to capture more of the end-market value created by its innovations and expertise.

**Micrima Ltd ('Micrima')** - Investment of £229,636 by way of convertible loan note held at fair value, for which cost is deemed the most appropriate basis of measurement.

Micrima specialises in radiofrequency technology to improve early diagnosis of breast cancer and measure breast density. Micrima continues to make progress, but has suffered delays in its commercial launch and as a consequence is looking to refocus on breast density measurement.

**Momentum Bioscience Ltd ("Momentum")** - Investment of £125,000 in preferred A ordinary shares, held at fair value, for which cost is deemed the most appropriate basis of measurement. Momentum undertook an additional subscription in September 2022 at the same valuation as IIG's investment.

Momentum is developing a revolutionary rapid diagnostic test for patients suspected of sepsis, an infection of the blood stream

resulting in symptoms including a drop in a blood pressure, increase in heart rate and fever. Momentum's SepsiSTAT® system enables reporting of the presence or absence and 'pan gram identification' of viable organisms in just two hours, helping direct the right antimicrobials. The system also provides a pure concentrate of growing organisms for further analysis. Faster testing in suspected sepsis patients can reduce mortality, accelerate hospital discharge, lower hospital costs, and reduce the incidence of antimicrobial resistance. SepsiSTAT® is a diagnostic test that runs from a sample of whole blood before any culturing steps are taken and is currently being studied in clinical practice with highly encouraging early results indicating competitive sensitivity versus the current standard of care. Over 120 million blood tests for sepsis are run annually representing a market potential of over £1 billion.

**Ocutec Ltd ('Ocutec')** - Investment of £250,000 in ordinary shares, held at fair value, for which cost is deemed the most appropriate basis of measurement. Post period Ocutec completed a fundraising of £1.2 million. The price was £2.00 per ordinary share which compares to a price of £1.60 per ordinary share at the time of the Company's investment. Therefore, there is a post period end unrealised gain of £62,500, based on most recent funding round.

Ocutec has patented technology covering the formulation of novel contact lens products, contact lens comfort solutions and injection moulding technology for rapid manufacturing. Ocutec is based in Glasgow, and has been operating since 2006, having been spun out of the University of Strathclyde.

**PneumoWave Ltd ('PneumoWave')** - Investment of £904,124 in new ordinary shares, held at fair value, for which last investment round is deemed the most appropriate basis of measurement. IIG invested £100,000 by way of convertible loan notes which converts at a 15% discount to the Series A and £350,000 in the pre-series A funding round. The Series A round has completed leading to an increase in valuation of £454,124.

PneumoWave, which was incorporated in February 2018, is developing an innovative remote respiratory monitoring platform comprising a small, chest-worn biosensor and AI-driven data analysis/alerting software for the early detection, prediction, and prevention of adverse events in respiratory patients, both in hospitals and at home. In 2020, PneumoWave was awarded Breakthrough Medical Device designation from the U.S. Food and Drug Administration for the development of the device, which is designed to monitor breathing in real-time to a clinical standard of care.

The specially designed wireless biosensor is one of the smallest available and transmits data to the cloud using a data hub or smartphone, alerting the patient, their household members, doctor, nurse, or emergency services where life-threatening changes occur. PneumoWave's technology will be able to accurately monitor large numbers of patients in any location at any time.

Source: IIG, [Prospectus](#), [RNS of 29 June 2023](#)

**THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.**

### **Conflicts**

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

### **Risk Warnings**

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

### **Specific disclaimers**

TPI acts as sole broker to Intuitive Investments Group plc ('IIG') which is listed on the AIM Market of the London Stock Exchange ('AIM'). TPI's private and institutional clients may hold, subscribe for or buy or sell IIG's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of IIG.

**General disclaimers**

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2023 Turner Pope Investments (TPI) Limited, all rights reserved.